[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immunologic-suppression\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immunologic-suppression":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100396964","immune-homeostasis-in-sepsis-and-septic-shock-100396964",false,"NCT04448951","Immune Homeostasis in Sepsis and Septic Shock","Immune Homeostasis in Patients With Sepsis and Septic Shock: a Single Center Observational Study","IMHOTEP","Inclusion Criteria:\n\n* sepsis\u002Fseptic shock (SEPSIS-3)\n* age ≥18\n* informed consent\n* inclusion within first 24hrs after development\u002Fdiagnosis of septic shock\n\nExclusion Criteria:\n\n* disagreement of the patient or legal representative with the entry into the study\n* patients with primary or secondary immunodeficiency\n* presence of active haematological malignancy or an active non-haematological malignancy",true,"ALL","18 Years",{"count":21,"type":22},200,"ESTIMATED","90 Days","OBSERVATIONAL","Detailed description of immune response and its dynamics in sepsis and septic shock patiens by means of transcriptomics, flow-cytometry and cytokine analysis.",[27,28,29,30],"Sepsis","Immunologic Paralysis","Immunologic Suppression","Immune Deficiency",[32,33,34,35,36,37,38],"sepsis","septic shock","immune response","immunoparalysis","transcriptomics","flow-cytometry","immunomodulation","RECRUITING","2024-08-20",{"date":42,"type":43},"2024-08-21","ACTUAL",{"date":45,"type":43},"2020-09-01",{"date":47,"type":22},"2027-12-31",{"name":49,"class":50},"Charles University, Czech Republic","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":18,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":67,"conditions":68,"keywords":73,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":51},"100348556","phase-2-post-transplant-cyclophosphamide-in-matched-unrelated-donor-stem-cell-transplantation-for-hematological-malignancies-100348556","NCT03818334","Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies","Use of Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies, a Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Men and Women of Any Age\n* Indication for an HSCT without matched sibling donor\n* Have a matched unrelated donor (HLA 10 x 10 or 9 x 10)\n* Hematological malignancy\n\nExclusion Criteria:\n\n* Acute leukemias not in complete response (that is \\> 5% blast in the bone marrow)\n* Chemorefractory lymphoproliferative disease\n* Active uncontrolled infection\n* HCT-CI \\> 3\n* Severe organic disfunction (heart ejection fraction \\\u003C 45%, glomerular filtration rate \\\u003C 50 mL.hour, pulmonary DLCO \\\u003C 50%)\n* Previous allogeneic bone marrow transplantation\n* Contraindication to cyclophosphamide or ATG","1 Year","75 Years",{"count":62,"type":22},50,"INTERVENTIONAL",[65,66],"PHASE2","PHASE3","This study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a bone marrow graft from a matched unrelated donor in overall survival, progression free survival and cumulative incidence of acute and chronic GvHD. Thirty patients will receive cyclophosphamide while twenty patients will receive antihuman T-lymphocyte immune globulin (ATG).",[69,70,71,72,29],"Bone Marrow Transplant Complications","Graft Versus Host Disease","Infection Viral","Engraft Failure",[74,75,76],"Bone Marrow Transplantation","Hematological Malignancies","Post-Cy","2019-01-31",{"date":79,"type":43},"2019-02-01",{"date":81,"type":43},"2018-11-06",{"date":83,"type":22},"2026-11-01",{"name":85,"class":50},"Hospital Israelita Albert Einstein"]